QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BMRN

QT67BioMarin Pharmaceutical Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
54.69
-0.33-0.60%
OverviewShort InterestFilings
BMRNQT67BioMarin Pharmaceutical Inc.·NASDAQ
OverviewShort InterestFilings
54.69-0.60%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E39.41EPS (ttm)
1.39
Insider Own1.16%
Shs Outstand193.28M
Perf Week-1.53%
Market Cap10.63BForward P/E8.33EPS next Y6.57Insider Trans-0.03%Shs Float-Perf Month9.80%
Enterprise Value9.85BPEG-EPS next Q0.96Inst Own-Short Float-Perf Quarter-0.62%
Income270.12MP/S3.28EPS this Y255.22%Inst Trans-Short Ratio-Perf Half Y5.64%
Sales3.24BP/B1.70EPS next Y32.99%ROA3.13%Short Interest-Perf YTD-7.98%
Book/sh32.14P/C12.11EPS next 5Y16.70%ROE4.41%52W High66.28 -17.49%Perf Year-0.56%
Cash/sh11.50P/FCF13.86EPS past 3/5Y-ROIC3.92%52W Low49.26 11.02%Perf 3Y-
Dividend Est.-EV/EBITDA20.42Sales past 3/5Y15.40% 11.61%Gross Margin75.93%Volatility1.53% 2.18%Perf 5Y-
Dividend TTM-EV/Sales3.04EPS Y/Y TTM-5.88%Oper. Margin13.55%ATR (14)1.67Perf 10Y-
Dividend Ex-Date-Quick Ratio4.20Sales Y/Y TTM13.59%Profit Margin8.29%RSI (14)49.18Recom2.21
Dividend Gr. 3/5Y-Current Ratio5.81EPS Q/Q-32.74%SMA20-0.77%Beta0.49Target Price89.93
Payout0.00%Debt/Eq0.23Sales Q/Q2.82%SMA500.80%Rel Volume1.66Prev Close55.02
Employees3,040LT Debt/Eq0.10EarningsAug 03SMA200-1.75%Avg Volume2.06MPrice54.69
IPO DateJul 26, 1999Option/ShortYes / YesEPS/Sales Surpr.-19.15% 1.73%Net Debt/EBITDA-1.62Volume3,422,284Change-0.60%
Analyst Ratings
DateActionAnalystRatingTarget
May-22-26ReiteratedCanaccord GenuityBuy$104 → $111
May-18-26ReiteratedLeerink PartnersMarket Perform$64 → $62
May-18-26ReiteratedH.C. Wainwright$55 → $50
May-11-26ReiteratedGoldman SachsBuy$69
May-05-26ReiteratedEvercore ISI$110 → $120
May-05-26ReiteratedTudor Pickering$94 → $82
Apr-27-26ResumedMorgan StanleyOverweight$98 → $120
Mar-12-26ReiteratedJefferiesBuy$103
Mar-02-26ReiteratedLoop Capital Markets$105
Feb-26-26ReiteratedCanaccord GenuityBuy$98 → $104
Latest News
Jun-16-26
Jun-16-2601:05PM
BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026Yahoo
09:13AM
BioMarin Pharmaceutical Presented New Data From Phase 2 Three-Year Extension Study Of VOXZOGO In 13 Children With Hypochondroplasia That Demonstrated Sustained Improvements In Annualized Growth Velocity And Height Standard Deviation ScoreBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue3,2423,2212,854
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A780737580
Gross Profit2,4612,4842,274
Selling, General and Administrative Excl. Other1,5601,2771,009
Research and Development941922747
Other Operating Expense-478-24833
Operating Income439533484
Interest Expense241113
Unusual Expense
———
Non-Operating Income (Expense)3040-70
Net Income Before Taxes386482542
Income Taxes116134115
Consolidated Net Income269349427
Net Income From Continuing Operations269349427
Net Income269349427
EPS (Recurring)1.401.822.25
EPS (Basic, Before Extraordinaries)1.401.822.25
EPS (Diluted)1.391.802.21
EBITDA483573651
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio39.3533.02—
Price To Sales Ratio3.243.54—
Gross Margin75.9177.1279.68
Operating Margin13.5416.5516.96
Net Margin8.3010.8414.96
Shares Outstanding192192190
Market Capitalization10,50011,411—
Operating Lease Expense
———
Insider Trading Volume
$57.59$51.67$45.75$39.84$33.92● Close Price0.00M0.50M0.99M1.49M1.98MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Friberg Gregory REVP, Chief R&D OfficerMay 07 '26Sale53.853,281176,68251,818May 11 12:00 AM
Guyer Charles GregEVP, Chief Technical OfficerMar 11 '26Sale60.4616,486996,74479,953Mar 12 12:00 AM
Davis George EricEVP, Chief Legal OfficerFeb 26 '26Sale61.3626,0611,599,10372,453Feb 26 12:00 AM
Friberg Gregory REVP, Chief R&D OfficerFeb 26 '26Sale60.386,326381,93737,578Feb 26 12:00 AM
Burkhart ErinGVP, Chief Accounting OfficerMay 20 '25Sale59.311,786105,92814,173May 20 12:00 AM
Hubbard CristinEVP, Chief Commercial OfficerMay 02 '25Sale64.9227317,72332,700May 06 12:00 AM
Burkhart ErinGVP, Chief Accounting OfficerMar 19 '25Sale71.521,29592,61816,955Mar 20 12:00 AM
Guyer Charles GregEVP, Chief Technical OfficerMar 06 '25Sale71.287,034501,35587,655Mar 07 12:00 AM
Burkhart ErinGVP, Chief Accounting OfficerFeb 24 '25Sale68.381,34491,90313,105Feb 25 12:00 AM
Guyer Charles GregEVP, Chief Technical OfficerNov 12 '24Sale66.375,278350,32468,909Nov 14 12:00 AM
Burkhart ErinGVP, Chief Accounting OfficerAug 13 '24Sale90.0071464,26014,449Aug 15 12:00 AM
HERON ELAINE JDirectorJun 03 '24Option Exercise63.1010,094636,932101,888Jun 04 12:00 AM
MEIER RICHARD ADirectorJun 03 '24Option Exercise63.1013,200832,920126,227Jun 04 12:00 AM
Mueller BrianEVP, Chief Financial OfficerMay 30 '24Option Exercise63.1010,000631,00077,159May 31 12:00 AM
Mueller BrianEVP, Chief Financial OfficerMay 30 '24Sale75.195,000375,95072,159May 31 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR